The proposal focuses on establishing point-of-care testing, increasing medication access among underserved populations, and engaging community organizations to drive awareness and increase screening.
A retrospective cohort study shows that GLP-1 agonists reduced the risk of cirrhosis and HCC in patients with MASLD and Type 2 diabetes.
New AASLD guidelines broadly recommend simple, cost-effective blood-based tests and elastography for many patients with chronic liver disease.
Simple blood-based tests can be used to identify which patients with MASLD should receive liver-directed therapy, but hepatologists may need more accurate measures, says Dr. Veeral Ajmera.
The Liver Meeting had ended, but your next opportunity to continue your hepatology education isn’t too far away.
Promoting gut health may improve outcomes in patients with cirrhosis, according to Dr. Jasmohan Bajaj.
GIs have an unprecedented opportunity to expand the quality of life for their patients.
Dr. Raymond Chung advises that continued vigilance is needed, even after the virus is gone.
Continue your liver education from the annual AASLD Liver Meeting® at DDW 2023.
Pandemic-related increases in alcohol use and AUDs warrant increased vigilance from hepatologists.
